Despite positive clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial difficulty from managed care entities. The companies are frequently creating limitations to reimbursement, like significant cost requirement